Stallergenes Greer : Q1 2019 sales: robust growth
>Q1 2019: +11.2%, ahead of our expectations - Q1 2019 sales came to € 84.7m, i.e. an increase of +11.2% (+9% at cc) with southern Europe sales at € 44.8m (+11.2%), Northern Europe at € 12.4m (+13.8%), the US at € 22.5m (+6.6%), while the other zones grew by +28.2%, lifted by Russia and Australia.Stallergenes-Greer confirmed its guidance for 2019, as issued on 21 March, with sales of between € 290m and € 300m, and EBITDA of between € 50m and € 60m.201...Stallergenes Greer is engaged in providing a comprehensive approach to allergies diseases, offering allergy specialists a range of products from diagnosis to sublingual and subcutaneous allergen immunothreaphy medicines. Co. portfolio comprises of four product categories; Sublingual products include ORALAIR® and STALORAL®; Subcutaneous products include ALUSTAL®, PHOSTAL®, ALYOSTAL ® and ALBEY®, and GREER EXTRACTS®; Veteninary product is a range of USDA-approved bulk extracts for animals suffering from a range of allergies; and Other products offer a variety of diagnostic tools and source materials in useful formulations for allergy specialists and physicians.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.